IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population
Lin, JT; Yu, XZ; Cui, DJ; Chen, XY; Zhu, JH; Wang, YZ; Wu, XD
关键词High-risk Population Influenza Oseltamivir Randomized Controlled Trial
刊名CURRENT MEDICAL RESEARCH AND OPINION
2006
DOI10.1185/030079906X820297
22期:1页:75-82
收录类别ISTP ; SCI
文章类型Proceedings Paper
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Medicine, Research & Experimental
研究领域[WOS]General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]CONGESTIVE-HEART-FAILURE ; IMPACT ; INFECTION ; COMPLICATIONS ; PREVENTION ; PNEUMONIA ; EFFICACY ; ONTARIO ; SAFETY ; VIRUS
英文摘要

Objective: To evaluate the efficacy and safety of oseltamivir treatment in a population at high risk for influenza.

Research design and methods: This was a randomized, open-label, controlled trial involving Chinese patients with chronic respiratory diseases (chronic bronchitis, obstructive emphysema, bronchial asthma or bronchiectasis) or chronic cardiac disease. Patients showing symptoms of influenza were randomly assigned to receive oral oseltamivir 75 mg twice daily for 5 days (oseltamivir group), or symptomatic treatment (control group) within 48 h after symptom onset.

Main outcome measures: The main outcome measures were duration and severity of illness in influenza-infected patients. Other outcome measures included incidence of complications, antibiotic use, hospitalization and total medical cost.

Results: Of the 118 recruited patients, 56 were identified as influenza-infected through laboratory tests (oseltamivir, N = 27; control, N = 29). Relative to symptomatic treatment, oseltamivir significantly reduced the duration of influenza symptoms by 36.8% (p = 0.0479), and the severity by 43.1% (p = 0.0002). In addition, oseltamivir significantly reduced the duration of fever by 45.2% (p = 0.0051), and the time to return to baseline health status by 5 days (p = 0.0011). The incidence of complications (11% vs. 45%, p = 0.0053) and antibiotic use (37% vs. 69%, p = 0.0167) were also significantly lower in the oseltamivir group compared with the control group. The cost of treating influenza and its complications was comparable between the two groups (p = 0.2462).

Conclusions: Oseltamivir is effective and well tolerated in high-risk patients with chronic respiratory or cardiac diseases. It can reduce the duration and severity of influenza symptoms and decrease the incidence of secondary complications and antibiotic use, without increasing the total medical cost.

语种英语
WOS记录号WOS:000234751400009
引用统计
被引频次:27[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57936
专题北京大学第一临床医学院
作者单位1.Beijing Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Tianjin Hosp Thorac Dis, Tianjin, Peoples R China
3.Tianjin 3 Med Ctr, Tianjin, Peoples R China
4.Peking United Med Ctr Hosp, Beijing, Peoples R China
5.China Japan Friendship Hosp, Dept Resp Dis, Beijing 100029, Peoples R China
6.Beijing Univ, Hosp 1, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Lin, JT,Yu, XZ,Cui, DJ,et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population[J]. CURRENT MEDICAL RESEARCH AND OPINION,2006,22(1):75-82.
APA Lin, JT.,Yu, XZ.,Cui, DJ.,Chen, XY.,Zhu, JH.,...&Wu, XD.(2006).A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population.CURRENT MEDICAL RESEARCH AND OPINION,22(1),75-82.
MLA Lin, JT,et al."A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population".CURRENT MEDICAL RESEARCH AND OPINION 22.1(2006):75-82.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lin, JT]的文章
[Yu, XZ]的文章
[Cui, DJ]的文章
百度学术
百度学术中相似的文章
[Lin, JT]的文章
[Yu, XZ]的文章
[Cui, DJ]的文章
必应学术
必应学术中相似的文章
[Lin, JT]的文章
[Yu, XZ]的文章
[Cui, DJ]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。